Abstract: The present disclosure relates to compounds that are Syk inhibitors or pharmaceutically acceptable salts or co-crystals thereof, and pharmaceutical compositions thereof, and to their use in the treatment of various disease states, including cancer and inflammatory conditions.

Abstract: An electronic device photographing method includes, after the electronic device enters a photographing screen, determining a folding angle of the flexible display screen based on a pixel coordinate parameter of a photographed object on the photographing screen; and/or determining target luminance of a display screen; and when detecting that a photographing button is pressed, adjusting luminance of the display screen to the determined target luminance. In this way, when the electronic device is used to take an image, fill-in light can be implemented for the photographed photo by improving target luminance of the display screen based on the pixel coordinate parameter of the photographed object on the photographing screen.

Abstract: Example adaption apparatus are described. An example adaption apparatus includes a first USB interface and a second USB interface. A power signal of the first USB interface is electrically connected to a power signal of the second USB interface. A first channel configuration signal of the first USB interface is electrically connected to an ID signal of the second USB interface using a first resistor. The ID signal of the second USB interface is electrically connected to the power signal of the second USB interface using a second resistor. A resistance value of the first resistor meets a criterion followed by a first device to identify a UFP device according to the USB Type-C protocol. A sum of the resistance value of the first resistor and a resistance value of the second resistor meets a criterion followed by the first device to identify a DFP device according to the USB Type-C protocol.

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Abstract: An LED light includes a body, a holder connected to the body, and a function extension unit detachably connected to the body. The holder includes a telescopic member stretched or contracted to adjust a length of the holder along an axial direction of the LED light. The present disclosure can solve technical problems that a conventional LED light can't be adapted to different installation environments. The function extension unit is configured to set different function modules to communicate with a power supply of the body according to needs of different customers so as to drive the body to change an output state of the power supply, thereby light emitting units of the body can work in different states. The present disclosure can further provide a smart driving system of an LED light to be customized to control a lighting mode of the body.

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Abstract: Embodiments of the present application disclose a camera lens and a camera. The camera lens is provided with a beam splitting device for splitting the incident light into visible light and near-infrared light. The camera lens is further provided with a group of variable magnification lenses and a group of compensation lenses, so that the zoom and aberration correction are achieved. The camera is provided with the camera lens for splitting the visible light and the infrared light. The camera is further provided with a visible light acquisition module for acquiring the visible light exiting from the camera lens and converting the visible light into a color signal and a first brightness signal. The camera is further provided with a near-infrared light acquisition module for acquiring the near-infrared light exiting from the camera lens and converting the near-infrared light into a second brightness signal.

Abstract: Example adaption apparatus are described. An example adaption apparatus includes a first USB interface and a second USB interface. A power signal of the first USB interface is electrically connected to a power signal of the second USB interface. A first channel configuration signal of the first USB interface is electrically connected to an ID signal of the second USB interface using a first resistor. The ID signal of the second USB interface is electrically connected to the power signal of the second USB interface using a second resistor. A resistance value of the first resistor meets a criterion followed by a first device to identify a UFP device according to the USB Type-C protocol. A sum of the resistance value of the first resistor and a resistance value of the second resistor meets a criterion followed by the first device to identify a DFP device according to the USB Type-C protocol.

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Abstract: An electronic device photographing method includes, after the electronic device enters a photographing screen, determining a folding angle of the flexible display screen based on a pixel coordinate parameter of a photographed object on the photographing screen; and/or determining target luminance of a display screen; and when detecting that a photographing button is pressed, adjusting luminance of the display screen to the determined target luminance. In this way, when the electronic device is used to take an image, fill-in light can be implemented for the photographed photo by improving target luminance of the display screen based on the pixel coordinate parameter of the photographed object on the photographing screen.

Abstract: An application uses an enhancer to shorten the half life and/or the complete degradation time of pesticide residue. During the whole growing period of crops or before seeding, the available mixture consisted of the pesticide preparation at 45%-100% of normal dose and the enhancer is applied for at least one time as the conventional way, in which the ratio of the pesticide preparation and the enhancer is 15-45000 g or ml/60-6000 ml per hectare. The enhancer is the mixture of Tween surfactants and N-R-2-pyrrolidone recorded in Chinese patent CN 96117683.0. Under the precondition of ensuring potency, and determining the usage amount of pesticide based on the occurrence circumstances of invasive pests, the present invention can reduce up to 55% dosage of pesticide, as well as the half life of pesticide residue and/or the complete degradation time by above 50%.

Abstract: Embodiments of this application disclose a battery leakage current check method, apparatus, and circuit, and relate to the battery field, so as to check for a leakage current inside a battery. The battery leakage current check method includes: when a power adapter supplies power to an electronic device, controlling the battery to stop supplying power to the electronic device; obtaining a voltage parameter and a duration parameter, where the voltage parameter is a difference between voltages of the battery at two different moments, and the duration parameter is duration between the two different moments; and determining, based on the voltage parameter and the duration parameter, whether a leakage parameter of the battery meets a preset condition. The embodiments of this application are applied to battery leakage current check.

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Abstract: The present disclosure relates generally to compounds (I) which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.

Abstract: The present disclosure relates to compounds that are Syk inhibitors and to their use in the treatment of various disease states, including cancer and inflammatory conditions. In particular embodiments, the structure of the compounds is given by Formula I: wherein R1, R2, R3, and R4 are as described herein. The present disclosure further provides pharmaceutical compositions that include a compound of Formula I, or pharmaceutically acceptable salts or co-crystals thereof, and methods of using these compounds and compositions to treat conditions mediated by Syk.

Abstract: Pyridone and aza-pyridone compounds of Formula I are provided, including stereoisomers, tautomers, and pharmaceutically acceptable salts thereof, useful for inhibiting Btk kinase, and for treating immune disorders such as inflammation mediated by Btk kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, and treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

Abstract: The present disclosure relates generally to compounds which bind to the NR1H4 receptor (FXR) and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.